Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Drug Investigation"
DOI: 10.1007/s40261-019-00820-6
Abstract: Background and ObjectivesIn first-line treatment of advanced renal cell carcinoma (aRCC), the KEYNOTE-426 study demonstrated a significant progression-free survival and overall survival for pembrolizumab plus axitinib in comparison with sunitinib. The objective of the current… read more here.
Keywords: pembrolizumab plus; cost; versus sunitinib; plus axitinib ... See more keywords
Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma
Sign Up to like & getrecommendations! Published in 2021 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2021.1903321
Abstract: ABSTRACT Introduction: The dominant paradigm of sequential therapy of metastatic renal cell carcinoma (mRCC) with single agents has recently been challenged by improved outcomes obtained with combined regimens with immune checkpoint inhibitors. These combined regimens… read more here.
Keywords: renal cell; pembrolizumab plus; cell carcinoma; plus axitinib ... See more keywords
Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial
Sign Up to like & getrecommendations! Published in 2021 at "Liver Cancer"
DOI: 10.1159/000514420
Abstract: Introduction: Combining an immune checkpoint inhibitor with a targeted antiangiogenic agent may leverage complementary mechanisms of action for the treatment of advanced/metastatic hepatocellular carcinoma (aHCC). Avelumab is a human anti-PD-L1 IgG1 antibody with clinical activity… read more here.
Keywords: hepatocellular carcinoma; treatment; liver 100; vegf liver ... See more keywords
A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2020.00619
Abstract: Background Compared with the standard of care with sunitinib, avelumab plus axitinib can increase progression-free survival in the first-line of advanced renal cell carcinoma (RCC), but the economic effect of the treatment is unknown. The… read more here.
Keywords: avelumab plus; first line; sunitinib; cost ... See more keywords